Q3 Earnings Forecast for Sanofi Issued By Leerink Partnrs

Sanofi (NASDAQ:SNY) – Equities researchers at Leerink Partnrs dropped their Q3 2025 earnings estimates for Sanofi in a note issued to investors on Tuesday, September 30th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings per share of $1.58 for the quarter, down from their prior estimate of $1.59. The consensus estimate for Sanofi’s current full-year earnings is $4.36 per share. Leerink Partnrs also issued estimates for Sanofi’s FY2025 earnings at $4.27 EPS.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The business had revenue of $11.34 billion during the quarter, compared to analysts’ expectations of $9.91 billion. During the same period in the previous year, the company posted $1.73 earnings per share. Sanofi’s quarterly revenue was down 7.0% on a year-over-year basis.

Several other brokerages also recently weighed in on SNY. Barclays reiterated an “overweight” rating on shares of Sanofi in a research note on Wednesday, July 2nd. Deutsche Bank Aktiengesellschaft raised Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 2nd. Wall Street Zen upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Morgan Stanley upgraded shares of Sanofi from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $56.00 to $58.00 in a research report on Monday, September 8th. Finally, JPMorgan Chase & Co. upgraded shares of Sanofi from a “neutral” rating to an “overweight” rating in a research note on Friday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Sanofi has a consensus rating of “Buy” and a consensus price target of $62.67.

Sanofi Stock Performance

Shares of SNY stock opened at $50.14 on Wednesday. The stock’s 50-day moving average price is $48.18 and its 200 day moving average price is $50.15. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $123.12 billion, a PE ratio of 12.05, a price-to-earnings-growth ratio of 1.18 and a beta of 0.51. Sanofi has a 52-week low of $44.62 and a 52-week high of $60.12.

Institutional Trading of Sanofi

A number of institutional investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Sanofi by 124.0% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,131 shares of the company’s stock valued at $1,344,000 after acquiring an additional 13,358 shares during the period. Axxcess Wealth Management LLC increased its stake in Sanofi by 130.5% in the 1st quarter. Axxcess Wealth Management LLC now owns 10,234 shares of the company’s stock valued at $568,000 after purchasing an additional 5,794 shares in the last quarter. Ballentine Partners LLC raised its holdings in Sanofi by 68.7% during the first quarter. Ballentine Partners LLC now owns 26,063 shares of the company’s stock worth $1,445,000 after purchasing an additional 10,617 shares during the last quarter. Voya Investment Management LLC raised its holdings in Sanofi by 11.6% during the first quarter. Voya Investment Management LLC now owns 206,635 shares of the company’s stock worth $11,460,000 after purchasing an additional 21,540 shares during the last quarter. Finally, Sowell Financial Services LLC purchased a new stake in Sanofi during the first quarter worth $328,000. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.